Catalyst Crew Technologies Corp. (OTC: CCTC) announced the assignment of three Venezuelan patents to its wholly-owned subsidiary, Inversiones Long 33, C.A., as part of a strategy to consolidate intellectual property within its operating structure. The patents, previously held by CEO Dr. Kevin Rodan Levy, cover technologies named CardioAI, PulmoAI, and NeuroAI—proprietary systems designed for data-driven healthcare analytics, predictive modeling, and clinical decision-support applications.
According to the company, this transfer positions the subsidiary as the primary vehicle for development and commercialization of its technology platform in the region. The company believes that consolidating IP at the operating level enhances strategic flexibility, supports regulatory alignment, and may facilitate future partnerships, licensing opportunities, and regional expansion initiatives. Additionally, Catalyst Crew intends to pursue broader intellectual property protection in other jurisdictions to support long-term platform development and potential international deployment.
Dr. Kevin Rodan Levy stated: “Aligning our intellectual property within our operating structure is an important step as we continue building our platform. Establishing a clear foundation around our core technologies allows us to move forward with development, partnerships, and, where appropriate, broader intellectual property protection strategies across additional markets.”
The company continues to advance its digital health and AI platform, focusing on scalable healthcare solutions including telehealth infrastructure, remote patient monitoring, and advanced analytics designed to improve access, efficiency, and care coordination. For more information, visit https://catalystcrewai.com or review the company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
This announcement is significant as it demonstrates Catalyst Crew's commitment to securing its intellectual property assets and aligning them with its operational strategy, which could strengthen its position in emerging markets. The consolidation of patents under the subsidiary may also enhance the company's ability to form strategic partnerships and licensing deals, potentially accelerating the deployment of its AI-driven healthcare solutions in Latin America and beyond. However, the company remains a development-stage enterprise with no revenues from its new business direction, and there is no assurance of successful implementation or regulatory approvals.
